BeiCell Therapeutics
北启生物
BeiCell Therapeutics (北启生物) is a cell therapy drug developer founded by Professor Hongkui Deng (邓宏魁), who serves as its chief scientist . The company is built on a chemical small-molecule induced pluripotent stem cell technology platform (CiPSC) aimed at developing globally innovative cell therapeutics . ZhenFund made an angel investment in the company and later participated in a 2022 funding round . Deng was elected to the Chinese Academy of Sciences in late 2025 and was named to TIME's 2025 TIME100 Health list of the most influential people in global health .
AI-generated — may contain errors, please verify.
Coverage
A Whole New World | Z News
We invite you to look back on the past month's "highlight reel" — a look at how our portfolio companies have grown and what's new at ZhenFund.
Greener Pastures, First Flickers of Ambition | Z News
The light and shadow grow richer; a story is brewing.
2024 Future Science Prize Winners Announced | Z News
Celebrating scientists and honoring the spirit of scientific inquiry.
